- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00074295
S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer
Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
RATIONALE: Vaccines made from a person's tumor tissue may make the body build an immune response to kill tumor cells.
PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with stage IIIB or stage IV bronchoalveolar (lung) cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the progression-free and overall survival of patients with selected stage IIIB or stage IV bronchoalveolar carcinoma treated with GVAX lung cancer vaccine.
- Determine the response rate (confirmed and unconfirmed and complete and partial) in patients treated with this vaccine.
- Determine the frequency and severity of toxic effects of this vaccine in these patients.
- Determine the functional status of patients treated with this vaccine.
- Correlate systemic biologic activity (i.e., antigen-specific antitumor and systemic cytokine responses) with clinical outcome in patients treated with this vaccine.
OUTLINE: This is a multicenter study. Patients are stratified according to prior systemic cancer therapy for bronchoalveolar carcinoma (BAC) (yes vs no) and pattern of BAC (diffuse vs nodular).
After successful vaccine manufacturing from tumor tissue procured, patients receive GVAX lung cancer vaccine intradermally (ID) (6-7 injections per vaccination) on weeks 1, 3, 5, 7, and 9 for a total of 5 vaccinations. Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and at weeks 9, 13, and 21.
Patients are followed at 4 weeks, every 8 weeks for 1 year, and then every 12 weeks for 2 years.
PROJECTED ACCRUAL: A total of 117 patients (67 previously untreated and 50 previously treated) will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis* of 1 of the following by radiological features and clinical presentation:
Bronchoalveolar carcinoma (BAC)
- Diffuse or ground glass appearance
- Adenocarcinoma with bronchoalveolar features
- BAC with focal invasion NOTE: *Histological confirmation (excluding fine needle aspiration or bronchial brushings or washings) is required after the tumor tissue has been procured and the vaccine has been produced
- Selected stage IIIB (due to malignant pleural effusion) OR stage IV disease
- Measurable or nonmeasurable disease (e.g., diffuse infiltrative process) by CT scan of the chest both before and after tumor tissue procurement for vaccine
- Not a candidate for curative resection
Tumor accessible for tissue procurement via thoracentesis or a surgical procedure
- If a pleural effusion is the source of tumor tissue, at least 600 mL of fluid must be available for vaccine manufacture
Resection of brain metastases may be used for vaccine processing
- Surgery must be done after study entry
- Asymptomatic previously treated (e.g., surgical resection or radiotherapy) brain metastases allowed provided the patient is neurologically stable
- No active or impending spinal cord compression or evidence of pericardial tamponade
PATIENT CHARACTERISTICS:
Age
- Over 18
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- CD4 count greater than 200/mm^3
- No bleeding disorder
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN) (3 times ULN if liver metastases are present)
- SGOT or SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases are present)
- Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if bone metastases are present)
Renal
- Not specified
Cardiovascular
- See Disease Characteristics
Patients requiring surgery for tumor tissue procurement must meet the following criteria:
- Pulmonary artery systolic pressure < 40 mm Hg by echocardiogram*
- LVEF > 40%
- No symptomatic congestive heart failure
- No thrombolic disorder
- No unstable angina pectoris
- No cardiac arrhythmia NOTE: *Not needed if patient has no tricuspid regurgitation
Pulmonary
- No pulmonary hypertension
- No significant baseline hypoxia (i.e., O_2 saturation less than 90% OR requires greater than 2 L/min of supplemental O_2 via nasal cannula) by an oxygen saturation test
- No postobstructive pneumonia
Patients requiring thoracoscopic surgery or thoracotomy for tumor tissue procurement must meet the following criteria:
- Alveolar partial pressure of CO_2 < 45 mm Hg
- Predicted postresection FEV_1 ≥ 1.0 L
- DLCO > 50% of predicted
Immunologic
- No active immune or autoimmune disease
- No systemic lupus erythematosus
- No sarcoiditis
- No rheumatoid arthritis
- No glomerulonephritis
- No vasculitis
- No serious infection
No hypersensitivity to any of the following:
- Sargramostim (GM-CSF)
- Pentastarch
- Gentamicin
- Human serum albumin
- Dimethyl sulfoxide
- Porcine trypsin
- Fetal bovine serum
- Recombinant benzonase
- Other components of the vaccine or CG6444 adenoviral vector used in this study
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No poor nutritional status
- No psychiatric illness or social situation that would preclude study compliance or increase operative risk
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
- No other concurrent uncontrolled illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 4 weeks since prior biologic therapy
- No prior gene therapy, including adenoviral-based therapy
Chemotherapy
More than 4 weeks since prior chemotherapy
- No prior regional chemotherapy administered through the pulmonary artery (if resection of the tumor in the treated lobe is planned)
Endocrine therapy
- More than 14 days since prior systemic corticosteroids
- No concurrent steroids
Radiotherapy
- See Disease Characteistics
More than 4 weeks since prior radiotherapy
- Disease must be outside the areas of prior radiotherapy OR clear progression at prior irradiated sites must be documented
- No prior radiotherapy to the tumor mass targeted for resection
Surgery
- See Disease Characteristics
- More than 7 days since prior surgery and recovered
Other
- More than 2 weeks since prior epidermal growth factor receptor inhibitors
- No other concurrent nonprotocol-specified treatment
- No concurrent immunosuppressants
- No concurrent chronic anticoagulation therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: treatment
GVAX lung cancer vaccine
|
6-7 injections per week in rotating locations for five weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Toxicity
|
Response rate
|
Functional status
|
Progression-free and overall survival
|
Correlation of systemic biologic activity with clinical outcome
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Raja Mudad, MD, FACP, Tulane University Health Sciences Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000343797
- U10CA032102 (U.S. NIH Grant/Contract)
- S0310 (OTHER: SWOG)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on GVAX lung cancer vaccine
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)Completed
-
NewLink Genetics CorporationNational Cancer Institute (NCI)CompletedLung Neoplasms | Adenocarcinoma of Lung | Non-small Cell Carcinoma | Squamous Cell Carcinoma | Large Cell CarcinomaUnited States
-
Guangdong Provincial People's HospitalUnknownLung Neoplasms | Venous ThromboembolismChina
-
Peking University Third HospitalCompletedParaneoplastic Neurological SyndromeChina
-
Duke UniversityCancer and Leukemia Group B; Durham VA Medical CenterCompletedSmoking Cessation | Tobacco Use Disorder | Lung CancerUnited States
-
NewLink Genetics CorporationTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
University Hospital, EssenCompleted
-
Providence Health & ServicesProvidence Cancer Center, Earle A. Chiles Research Institute; Cell GenesysUnknown
-
Centre Leon BerardThe Biostatistics and Therapy Evaluation Unit; BEC (Department of Clinical...CompletedBreast Cancer | Lung CancerFrance
-
Korea University Guro HospitalCompletedExpression of Integrin ανβ3 in Lung CancerKorea, Republic of